CTOs on the Move

CityVet™

www.cityvet.com

 
CityVet Veterinary Care - exceptional care with services include Boarding, Bathing, Grooming, Veterinary Care and Food & Supplies with locations in Dallas, TX, Houston, TX and Denver, CO.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.cityvet.com
  • 3101, McKinney Avenue
    Dallas, TX USA 75204
  • Phone: 214.522.0030

Executives

Name Title Contact Details

Similar Companies

US Re Corporation

US Re Corporation is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Houston, TX. To find more information about US Re Corporation, please visit www.usre.com

BewellConnect Corp

BewellConnect Corp. is an ecosystem of connected devices and services that enhance care coordination.

Horizon Blue Cross Blue Shield of New Jersey

Horizon Blue Cross Blue Shield of New Jersey, the only licensed Blue Cross and Blue Shield plan in New Jersey, provides health insurance coverage to more than 3.6 million people throughout all of North, Central, and South Jersey. Horizon Blue Cross Blue Shield of New Jersey is best known for our managed care and traditional indemnity plans for individuals and employers — the cornerstone of our health care business. Horizon BCBSNJ traces its history back to 1932 when Associated Hospitals of Essex County, Inc. was formed as a multi-hospital prepayment plan. The company later became the nation`s first Blue Cross Plan. Horizon Blue Cross Blue Shield of New Jersey, is a not-for-profit, health service corporation. A 15-member Board of Directors governs the company for its members. There are no shareholders.

Grane Rx

Grane Rx is a leader in long term care pharmacy solutions and services, supporting long term care communities and PACE providers. Grane Rx offers LTC pharmacy solutions and PACE pharmacy solutions for Pennsylvania, North Carolina, Massachusetts, New Je...

Envisia Therapeutics

Envisia Therapeutics, formed by Liquidia Technologies in 2013, is a privately held biotechnology company focused on the development of novel ocular therapies. Envisia is leveraging the unique and powerful properties of the PRINT® platform to develop therapies for a variety of ocular conditions, the most advanced of which is ENV515, for the treatment of glaucoma. ENV515 is a novel extended-release formulation of a prostaglandin analogue formulation. It has the potential to significantly limit disease progression and vision loss through improved product performance and patient compliance. Envisia is located in Research Triangle Park, North Carolina.